CytomX Therapeutics develops cancer treatments using its PROBODY masked biologics platform. It last closed at $2.03 on Nov 20, down 0.98% on the day. The next earnings report for CTMX is expected around Mon, Mar 15, 2027. Over its last 8 reports the stock moved an average of 11.5% the session after earnings. Over the last 12 months CTMX insiders bought $0 of stock on the open market and sold $1.2M, according to SEC Form 4 filings.
AI Auto Pilots
Is CTMX in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold CTMX.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on CTMXStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
CTMX · as of the Nov 20 close · updated each morning
Downtrend
The stock is 5% below its 20 day and 19% below its 50 day average. It is 78% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 42). The nearest support is the Pivot S1 at $1.94, and the nearest resistance the Pivot at $2.05.
Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityHigh, 8.8%/day
Key levels
$8.2152 week high+304.4%
$3.61200 day average+77.8%
$2.94100 day average+44.8%
$2.42Swing high (Oct 29)+19.2%
$2.4150 day average+18.7%
$2.14Pivot R1+5.4%
$2.1320 day average+4.9%
$2.05Pivot+1.0%
$2.03Last close
$1.94Pivot S1−4.4%
$1.90Swing low (Nov 10)−6.4%
$1.8752 week low−7.9%
Indicators
RSI (14)
42.41
Middle of its range
Neutral
MACD
-0.14
Above its signal line
Bullish
Stochastic
23.1
Middle of its range
Neutral
ADX (14)
21.7
Weak trend
Williams %R
-67.3
Oversold below −80, overbought above −20
Neutral
CCI (20)
-49.9
Oversold below −100, overbought above 100
Neutral
Rate of change
−7.3%
Change over 10 sessions
Bearish
ATR (14)
$0.18
Typical daily range, 8.8% of price
MA 10Above
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Pullback inside a longer uptrend, nearing oversold
Short trendBearish
Long trendBullish
MomentumWeak
StretchNear oversold
VolatilityNormal, 21.2%/day
Key levels
$8.2152 week high+304.4%
$3.61200 day average+77.8%
$2.94100 day average+44.8%
$2.42Swing high (Oct 29)+19.2%
$2.4150 day average+18.7%
$2.14Pivot R1+5.4%
$2.1320 day average+4.9%
$2.05Pivot+1.0%
$2.03Last close
$1.94Pivot S1−4.4%
$1.90Swing low (Nov 10)−6.4%
$1.8752 week low−7.9%
Indicators
RSI (14)
30.71
Weak, oversold below 30
Neutral
MACD
-0.44
Below its signal line
Bearish
Stochastic
6.5
Near the bottom of its range
Oversold
ADX (14)
21.3
Weak trend
Williams %R
-92.1
Oversold below −80, overbought above −20
Oversold
CCI (20)
-120.3
Oversold below −100, overbought above 100
Oversold
Rate of change
−38.3%
Change over 10 sessions
Bearish
ATR (14)
$0.43
Typical daily range, 21.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for CTMX
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how CTMX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow CTMX usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for CTMXHow many large options trades hit CTMX, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in CTMX in the last 90 days.
From SEC Form 4 filings by CTMX's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CTMX is in one of them and how their past CTMX trades turned out.
CytomX Therapeutics is a biopharmaceutical company based in South San Francisco, California, that develops cancer treatments. It uses its PROBODY platform to build masked biologic therapies, which are designed to bind more selectively within tumors and limit effects on healthy tissue. Its most advanced candidate, Varsetatug Masetecan, is an antibody drug conjugate being studied in colorectal cancer, with plans to test it in other solid tumors. The company's therapies are aimed at cancer patients.